טוען...
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France
PURPOSE: Baclofen is widely used off‐label for alcohol use disorders (AUD) in France, despite its uncertain efficacy and safety, particularly at high doses. This study was designed to evaluate the safety of this off‐label use compared to the main approved drugs for AUD (acamprosate, naltrexone, nalm...
שמור ב:
| הוצא לאור ב: | Pharmacoepidemiol Drug Saf |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282718/ https://ncbi.nlm.nih.gov/pubmed/30251424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4635 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|